Galapagos shares are tumbling following disappointing results from a cystic fibrosis trial.

Galapagos N.V. (NASDAQ:GLPG) is developing new triplet combination therapies with AbbVie(NYSE:ABBV) for cystic fibrosis that the two companies hope can challenge Vertex Pharmaceuticals (NASDAQ:VRTX) someday. Unfortunately, the results reported yesterday from a mid-stage study did not inspire confidence.